Global Dermatology Treatment Devices Market will cross USD 9,389.73 million by 2025. It was valued at USD 4,016.47 million in 2017. The market is growing at a CAGR of 11.3% in the forecast period 2018 to 2025
The global dermatology treatment devices market highly concentrated to a few big players and rest to local players who cater to domestic markets only. Syneron Medical Ltd dominated the dermatology treatment device market accounting for a highest market share in 2017, followed by Cutera Inc and Valeant Pharmaceuticals International Inc. Other players in this market include are Beijing Toplaser Technology Co, Ltd., Avita Medical, Biofrontera AG , Sciton Inc., Lumenis, Alma Lasers, Radiancy, Inc. among others.
Syneron Medical Ltd:
Founded in 2000 and headquartered in Massachusetts, U.S. SYNERON MEDICAL LTD. is engaged in global non-surgical aesthetic device with a comprehensive product portfolio with footprints in global distribution. It provides various advance solutions for medical-aesthetic including improving the skin's appearance, treatment of superficial benign vascular and pigmented lesions, body contouring, hair removal, wrinkle reduction, tattoo removal, the treatment of acne, leg veins and cellulite, women's intimate health and others. Company’s products are entirely based on laser, ultrasound, and radiofrequency. The company‘s product line includes CO2RE, CO2RE Intima, GentleLase, and others.
In 2017 Syneron Medical Ltd. announced the acquisition by an affiliate of funds advised by Apax Partners. The company has a strong geographic presence across the globe. Some of the subsidiaries are Candela Corp(U.S.), Syneron China (China), Rakuto Bio Technologies Ltd. (Israel), TransPharma Medical Ltd.(Israel), Ultrashape Ltd.( Israel), Syneron Beauty, Inc. (Israel) and others.
Cutera Inc. was instituted in 1998 and headquartered at California, U.S. The company is involved in designing, development, manufacturing and commercialization of laser and other energy based aesthetic medical products. The core focus of company is in dermatology segment. It offers products for the treatment of rosacea, angiomas, port wine stains (pws), venous lakes, facial veins, leg veins, poikiloderma, inflammatory acne, lentigines, freckles, dpns, age/brown spots, skin tags, acne scars, scar reduction, wrinkles, warts, dermal heating, hair removal, tattoo removal, epidermal and dermal pigmentation, pico genesis, telangiectasia, deep tissue heating, reduced appearance of cellulite, and circumferential reduction.
Few subsidiaries of Cutera Inc are Cutera Japan (Japan), Cutera UK limited (United kingdom), Cutera Hong Kong Limited (Hong Kong), Cutera Belgium (Belgium), Cutera Australia Pty Ltd (Australia), Cutera Germany Gmbh (Germany) and among others.
Cutera Inc. provides products and services across U.S, Australia, Belgium, Canada, France, Hong Kong, Japan, Spain, and United Kingdom along with the online stores facility for the users
Valeant Pharmaceutical International Inc:
Valeant Pharmaceuticals International, Inc. was established in 1960 and headquartered in New Jersey, U.S. The company manufactures and supplies a wide range of pharmaceutical, medical device and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology and dermatology. The company mainly has three business segments namely Bausch + Lomb/International, Branded Rx and U.S Diversified products. The Bausch + Lomb/International segment comprises of pharmaceutical products, OTC products and medical device products mainly covering Bausch + Lomb products with the focus on Vision Care, Surgical & Consumer and Ophthalmology products. The second segment Branded Rx consists of Salix products (gastrointestinal (“GI”) products), Ortho Dermatologics (dermatological products) & oncology (or Dendron), dentistry and women’s health products (or Sprout). The U.S. Diversified Products segment includes pharmaceutical products, OTC products and medical device products for neurology and certain other therapeutic classes, including the Solta business and the Obagi business. The company also sells his dermatological devices through its subsidiary company named Solta Medical.
The company has subsidiaries worldwide. Some of them are Valeant Pharmaceuticals Ireland Limited (Ireland), Valeant China Inc. (China), Valeant Pharmaceuticals New Zealand Limited (New Zealand), Solta Medical (U.S), Obagi Medical (U.S) and many more. The company has strong geographic presence in U.S., Puerto Rico, China, Japan, Mexico, Poland, Russia, France, Germany, Egypt, Australia, United Kingdom and Brazil.
Global Dermatology Treatment Devices Market – Industry Trends and Forecast to 2027
North America Dermatology Treatment Devices Market - Industry Trends and Forecast to 2025
Europe Dermatology Treatment Devices Market - Industry Trends and Forecast to 2025
Asia-Pacific (APAC) Dermatology Treatment Devices Market - Industry Trends and Forecast to 2025